Ricerca Biosciences Finalizes Acquisition of MDS Pharma Services Business
Ricerca Biosciences, LLC, announced today the finalization of the acquisition of the Discovery and Preclinical business of MDS Pharma Services with facilities and almost 600 associates in Bothell, Washington; Lyon, France; and Taipei, Taiwan.
The expanded organization provides the biopharmaceutical industry with access to a global contract research organization (CRO) focused on the developmental phase between intellectual property (IP) and submission of the investigational new drug (IND) application. The increased capacity and capabilities delivers benefits such as:
• Global toxicology allowing coordination of projects between North America, Europe and Asia
• Access to cGMP and non-GMP API synthesis and process development for INDenabling toxicology performed in North America and Europe
• Expanded DMPK services and efficacy models
• Streamlined lead optimization service combining efficacy and biomarker assays withmedicinal chemistry
• Complete pharmacological profiling services including molecular, cellular, tissue and in vivo assays of development candidates
• Radio labeled compound synthesis available for all locations worldwide
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
